Weight loss injections may curb alcohol cravings—but at what cost?

Weight loss injections like Wegovy and Mounjaro are gaining traction in the UK and Germany. These GLP-1 receptor agonists mimic a hormone controlling hunger and blood sugar. However, their use comes with strict rules and some unexpected side effects.

The drugs work by suppressing appetite, slowing digestion, and boosting insulin production, helping lower blood sugar and reducing cravings. They also block the feel-good hormones triggered by snacking. In Germany, statutory health insurance doesn't cover Wegovy for weight loss, considering it a lifestyle drug.

A recent study found another effect: patients on these injections felt less intoxicated and absorbed alcohol more slowly. Their breath alcohol levels rose at a reduced rate compared to those not taking the medication. Researchers suggest the drugs could help heavy drinkers cut back by dulling alcohol's impact.

Access to these treatments varies. In the UK, NHS prescriptions are limited to specialist clinics, targeting patients with a BMI of 30 or above and a weight-related condition. Private prescribers, meanwhile, offer the injections to anyone obese or overweight with a health risk—after a video or in-person consultation.

Yet concerns persist. As of January 2025, UK authorities investigated 85 suspected deaths linked to the drugs. Common side effects include gut problems, altered taste, and kidney issues. Rare but severe cases involve allergic reactions or acute pancreatitis.

The injections continue to be prescribed under strict conditions, with ongoing research into their broader effects. While they may help some reduce alcohol intake, their risks and limited insurance coverage keep access tightly controlled. Officials and prescribers are monitoring their long-term impact closely.